Products and methods for treating metabolic, cardiovascular, inflammatory and oncological diseases
Patent Information
- Application Number
- HK62026126312
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-07-17
- Publication Date
- 2026-09-11
Smart Images

Figure 00000062_0000 
Figure 00000062_0001 
Figure 00000062_0002
Abstract
Description
The abstract provides tripeptide products for use in combination with fecal bacteria in the treatment of metabolic, cardiovascular, inflammatory, and oncological diseases.
Claims
1.A method of treating a metabolic, cardiovascular, inflammatory or oncological disease in a subject comprising administering to the subject a Gly-Gly-Leu tripeptide and a Faecalibacterium.2.The method of claim 1 wherein the Faecalibacterium is Faecalibacterium prausnitzii.3.The method of any preceding claim wherein the disease is a hepatic disease.4.The method of claim 3 wherein the hepatic disease is nonalcoholic fatty liver disease (NAFLD) .5.The method of claim 3 wherein the disease is nonalcoholic steatohepatitis (NASH) .6.The method of claim 3 wherein the treatment lowers, or inhibits the progression of, hepatic steatosis, lobular inflammation, hepatocellular ballooning, NAFLD activity score (NAS) and / or fibrosis score.7.The method of claim 1 or 2 wherein the disease is a biliary disease.8.The method of claim 7 wherein the disease is primary biliary cirrhosis.9.The method of claim 7 wherein the disease is biliary cholangiatis.10.The method of any preceding claim wherein the treatment reduces the production of one or more secondary bile acids in the subject.11.The method of claim 10 wherein the production of lithocholic acid is reduced.12.The method of any preceding claim wherein the treatment decreases the abundance of Escherichia Shigella in the gut of the subject.13.The method of any preceding claim wherein the subject is a primate.14.The method of claim 13 wherein the primate is a human.15.The method of claim 14 wherein about 1 to about 500 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.16.The method of claim 14 wherein about 3 to about 144 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.17.The method of claim 14 wherein about wherein about 1 to about 100 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.18.The method of claim 14 wherein about wherein about 12 to about 36 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.19.The method of claim 14 wherein about wherein about 37.5 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.20.The method of any preceding claim wherein the Gly-Gly-Leu tripeptide is administered orally.21.The method of any preceding claim wherein the Gly-Gly-Leu tripeptide is administered in a single dose.22.A method of reducing the production of one or more secondary bile acids in a subject comprising administering to the subject a Gly-Gly-Leu tripeptide and a Faecalibacterium.23.The method of claim 22 wherein the production of lithocholic acid is reduced.24.The method of claim 22 wherein the subject is a primate.25.The method of 24 wherein the primate is a human.26.The method of claim 25 wherein about 1 to about 500 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.27.The method of claim 25 wherein about 3 to about 144 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.28.The method of claim 25 wherein about wherein about 1 to about 100 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.29.The method of claim 25 wherein about wherein about 12 to about 36 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.30.The method of claim 25 wherein about wherein about 37.5 mg / kg / day of Gly-Gly-Leu tripeptide is administered to the subject.31.The method of any of claim 22-30 wherein the Gly-Gly-Leu tripeptide is administered orally.32.The method of any of claims 22-31 wherein the Gly-Gly-Leu tripeptide is administered in a single dose..
